Tempest Therapeutics Files 2024 Annual Report Amendment

Ticker: TPST · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1544227

Tempest Therapeutics, Inc. 10-K/A Filing Summary
FieldDetail
CompanyTempest Therapeutics, Inc. (TPST)
Form Type10-K/A
Filed DateApr 30, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: amendment, annual-report, pharmaceutical

TL;DR

Tempest Therapeutics amended its 2024 10-K filing on April 30, 2025. Check for updates.

AI Summary

Tempest Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024, on April 30, 2025. The company, formerly known as OvaScience, Inc. and Millendo Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. This filing provides updated information regarding its financial performance and business operations for the year 2024.

Why It Matters

This amendment to the annual report provides updated and potentially revised information for investors and stakeholders regarding Tempest Therapeutics' financial health and operational status as of December 31, 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Tempest Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

  • 2024-12-31 — Fiscal Year End (The period covered by the annual report.)
  • 2025-04-30 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

  • Tempest Therapeutics, Inc. (company) — Registrant
  • 2024-12-31 (date) — Fiscal year end
  • 2025-04-30 (date) — Filing date
  • OvaScience, Inc. (company) — Former company name
  • Millendo Therapeutics, Inc. (company) — Former company name
  • Delaware (location) — State of incorporation
  • 45-1472564 (identifier) — EIN
  • 001-35890 (identifier) — Commission File Number

FAQ

What specific changes or updates are included in this 10-K/A amendment?

The filing is an amendment (No. 1) to the annual report for the fiscal year ended December 31, 2024, indicating that the original filing may have contained errors or omissions that are now being corrected or supplemented.

What was Tempest Therapeutics, Inc. previously known as?

Tempest Therapeutics, Inc. was formerly known as Millendo Therapeutics, Inc. and prior to that, OvaScience, Inc.

In which state is Tempest Therapeutics, Inc. incorporated?

Tempest Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Tempest Therapeutics, Inc.?

The Commission File Number for Tempest Therapeutics, Inc. is 001-35890.

What is the primary business of Tempest Therapeutics, Inc. according to the SIC code?

According to the Standard Industrial Classification (SIC) code, Tempest Therapeutics, Inc. operates in 'PHARMACEUTICAL PREPARATIONS [2834]'.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Tempest Therapeutics, Inc. (TPST).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.